Abbott adds Kevin Conroy to board; shareholders approve 2026 Incentive Stock Program

ABBOTT LABORATORIES

Kevin Conroy appointed to Abbott's Board of Directors effective April 24, 2026.
Shareholders approved the 2026 Incentive Stock Program authorizing up to 140 million shares, replacing the 2017 plan.
Board size increased from 12 to 13 directors via bylaw amendment effective April 24, 2026.
The 2026 Program has a ten-year term and permits stock options, RSUs, performance awards, and other equity grants.
All director nominees were elected; Ernst & Young ratified as independent auditor.

item 5.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ABBOTT LABORATORIES: Board size increased from twelve to thirteen directors (effective 2026-04-24).

Change: bylaw amendment
Effective: 2026-04-24

Exact text from the filing

On April 24, 2026, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of thirteen persons, effective April 24, 2026.

View on SEC.gov

Browse all governance changes →

ABBOTT LABORATORIES filing history →

Source: SEC EDGAR

accession 0001104659-26-049434

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.